Trifluridine/tipiracil (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Trifluridine/tipiracil" in English language version.

refsWebsite

Global rank English rank

7nih.gov

4^th place

4doi.org

2^nd place

3semanticscholar.org

11^th place

8^th place

2tga.gov.au

3,984^th place

2,622^nd place

2europa.eu

68^th place

117^th place

1hres.ca

low place

1medicines.org.uk

3,823^rd place

2,387^th place

1fda.gov

447^th place

338^th place

1web.archive.org

1^st place

doi.org

Temmink OH, Emura T, de Bruin M, Fukushima M, Peters GJ (June 2007). "Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies". Cancer Science. 98 (6): 779–89. doi:10.1111/j.1349-7006.2007.00477.x. PMC 11158373. PMID 17441963. S2CID 19183535.
Peters GJ, Bijnsdorp IV (December 2012). "TAS-102: more than an antimetabolite". The Lancet. Oncology. 13 (12): e518-9. doi:10.1016/s1470-2045(12)70426-6. PMID 23182191.
Hoff PM, Cassidy J, Schmoll HJ (1 August 2001). "The evolution of fluoropyrimidine therapy: from intravenous to oral". The Oncologist. 6 Suppl 4 (90004): 3–11. doi:10.1634/theoncologist.6-suppl_4-3. PMID 11585968. S2CID 12355316.
Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, et al. (September 2006). "Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors". Cancer. 107 (6): 1383–90. doi:10.1002/cncr.22125. PMID 16902987. S2CID 32214949.{{cite journal}}: CS1 maint: overridden setting (link)

europa.eu

ema.europa.eu

"Lonsurf EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 20 October 2020.
"Lonsurf EPAR – Summary for the Public" (PDF). European Medicines Agency. April 2016. Archived from the original (PDF) on 18 June 2018. Retrieved 27 September 2016.

fda.gov

"FDA approves new oral medication to treat patients with advanced colorectal cancer" (Press release). Silver Spring, MD. U.S. Food and Drug Administration. 22 September 2015. Retrieved 23 September 2015.

hres.ca

hpr-rps.hres.ca

"Regulatory Decision Summary for Lonsurf". 23 October 2014.

medicines.org.uk

"UK Label: Lonsurf - Summary of Product Characteristics". Electronic Medicines Compendium. August 2017. Retrieved 10 May 2018.

nih.gov

pubmed.ncbi.nlm.nih.gov

Temmink OH, Emura T, de Bruin M, Fukushima M, Peters GJ (June 2007). "Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies". Cancer Science. 98 (6): 779–89. doi:10.1111/j.1349-7006.2007.00477.x. PMC 11158373. PMID 17441963. S2CID 19183535.
Peters GJ, Bijnsdorp IV (December 2012). "TAS-102: more than an antimetabolite". The Lancet. Oncology. 13 (12): e518-9. doi:10.1016/s1470-2045(12)70426-6. PMID 23182191.
Matsushita S, Nitanda T, Furukawa T, Sumizawa T, Tani A, Nishimoto K, et al. (April 1999). "The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors". Cancer Research. 59 (8): 1911–6. PMID 10213500.{{cite journal}}: CS1 maint: overridden setting (link)
Hoff PM, Cassidy J, Schmoll HJ (1 August 2001). "The evolution of fluoropyrimidine therapy: from intravenous to oral". The Oncologist. 6 Suppl 4 (90004): 3–11. doi:10.1634/theoncologist.6-suppl_4-3. PMID 11585968. S2CID 12355316.
Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, et al. (September 2006). "Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors". Cancer. 107 (6): 1383–90. doi:10.1002/cncr.22125. PMID 16902987. S2CID 32214949.{{cite journal}}: CS1 maint: overridden setting (link)

dailymed.nlm.nih.gov

"Lonsurf- trifluridine and tipiracil tablet, film coated". DailyMed. 14 January 2020. Retrieved 20 October 2020.

ncbi.nlm.nih.gov

Temmink OH, Emura T, de Bruin M, Fukushima M, Peters GJ (June 2007). "Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies". Cancer Science. 98 (6): 779–89. doi:10.1111/j.1349-7006.2007.00477.x. PMC 11158373. PMID 17441963. S2CID 19183535.

semanticscholar.org

api.semanticscholar.org

Temmink OH, Emura T, de Bruin M, Fukushima M, Peters GJ (June 2007). "Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies". Cancer Science. 98 (6): 779–89. doi:10.1111/j.1349-7006.2007.00477.x. PMC 11158373. PMID 17441963. S2CID 19183535.
Hoff PM, Cassidy J, Schmoll HJ (1 August 2001). "The evolution of fluoropyrimidine therapy: from intravenous to oral". The Oncologist. 6 Suppl 4 (90004): 3–11. doi:10.1634/theoncologist.6-suppl_4-3. PMID 11585968. S2CID 12355316.
Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, et al. (September 2006). "Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors". Cancer. 107 (6): 1383–90. doi:10.1002/cncr.22125. PMID 16902987. S2CID 32214949.{{cite journal}}: CS1 maint: overridden setting (link)

tga.gov.au

"Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
"Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.

web.archive.org

"Lonsurf EPAR – Summary for the Public" (PDF). European Medicines Agency. April 2016. Archived from the original (PDF) on 18 June 2018. Retrieved 27 September 2016.